Great viewpoints on two different types cultures -- large, multinational and startups -- offered by Charlie Attlan, Boston Scientific & Andrew Cleeland, Fogarty Innovation, led by Cynthia Yee, Vensana Capital:
- Charlie spoke of how culture starts at the top with Mike Mahoney -- his attention to detail, M&A, being reactive and willing to take risks. Emphasis is on being a team player, owning it together and never pointing fingers. The focus isn't inward, looking back & blaming but an "all in this and grinding through it together" mentality is what he needs for his team to work.
- Andrew spoke of the "one mission" and how critical that is when tough decisions need to be made. The magic happens "on the bench" so conversations around the bench need to happen and working from home doesn't support that one mission. That is different than being flexible.
Diversity on viewpoints and opinions across the company speaks to Charlie's view of a solid, diverse culture more so that focusing on diversity as it relates to groups or individuals who feel (or may be) marginalized.
Two great leaders, both equally invested in creating unified cultures.
This draws to mind that we must also remember that culture begins with each individual person, too: their world view, adaptability, upbringing, life experiences, values, and what they deem as important.
Having a visceral understanding of this before hiring them is essential as it will impact how they behave and perform in that new company culture...
As an investor at Vensana Capital, my conversation with Charlie Attlan who leads corporate strategy and business development at Boston Scientific, and Andrew Cleeland, who is CEO of Fogarty Innovation and a successful serial entrepreneur, highlighted the ongoing collaboration between VCs, start ups and large corporate medtech that is necessary to support growth and innovation in the #medtech industry.
Culture for risk taking with shared responsibility when things don't go according to plan allows novel ideas to thrive. In today's constrained economic environment with rising cost of capital, we must not forget that start-ups are the engines for large cap company growth, so let's get creative on deal structure and find that next build to buy opportunity for Boston Scientific.
CEO Collective Audience NASDAQ: CAUD, Founder, Board Member, Investor, managing partner Trajectory Ventures & Trajectory Capital
3wExciting times! I am so thrilled to be a part of this disruptive innovation journey!!🚀🚀 Building the dial tone of data for the open web.